Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge
Metabolic and Central Nervous System Characterisation of the Phenotype of Non-suppressed (Rising) Glucagon After Glucose Challenge
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tübingen, Germany, 72076
- University Hospital Tübingen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI 18.5- 29.9 kg/m2
- written informed consent
Exclusion Criteria:
Current
- febrile infection with temperatures> 38.5 ° C in the last 14 days
- Blood donation within the last 12 weeks Pre-study Inclusion
Chronic diseases:
- Diabetes mellitus
- Known liver diseases (hepatitisB/C, hemochromatosis, NASH)
- Chronic inflammatory diseases (rheumatoid arthritis, Crohn's disease, ulcerative colitis) chronic renal insufficiency
- Cancer (known malignant disease)
- psychiatric diagnoses (bipolar disorder, schizophrenia, psychoses, depression, agoraphobia)
Persons with non-removable metal parts, e.g:
- pacemaker
- artificial heart valves
- metal prostheses
- implanted magnetic metal parts (screws, plates of operations)
- spiral
- metal slivers / garnet splinters
- fixed braces
- Acupuncture needle
- Insulin pump
- totally implantable venous access device (port)
- tattoos, metallic eye shadows
- Persons with impaired sensitivity and / or increased sensitivity to heating of the body
- Medical history of venous thromboembolism
- alcohol consumption of more than 50g / day
In physical examination:
blood pressure > 160/100 mmHg pathologic cardiac murmurs (diastolic or systolic louder than 2/6)
- in the blood test: fasting glucose ≥ 125 mg/dl or HbA1c ≥ 6.5% AST or ALT> 2.5x upper limit of the reference range (> 125 U/l) Hb <12 g/dl C reactive protein (CRP) > 5 mg / dL or leukocytes> 15000/μl
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Intravenous glucagon
Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
|
Randomized application of glucagon or saline during oral glucose tolerance test
|
|
Placebo Comparator: Intravenous saline
Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
|
Randomized application of glucagon or saline during oral glucose tolerance test
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brain activity
Time Frame: change from baseline to 120 minutes after oral glucose challenge
|
Resting-state brain activity assessed by fMRI
|
change from baseline to 120 minutes after oral glucose challenge
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hunger rating
Time Frame: before and 150 minutes after oral glucose challenge and start of glucagon/saline infusion
|
On visual analogue scale
|
before and 150 minutes after oral glucose challenge and start of glucagon/saline infusion
|
|
Brain response to food cues
Time Frame: before, 30 minutes and 120 minutes after oral glucose challenge and start of glucagon/saline infusion
|
Assessed by functional magnetic resonance imaging (fMRI)
|
before, 30 minutes and 120 minutes after oral glucose challenge and start of glucagon/saline infusion
|
|
Glucose tolerance
Time Frame: 0-120 minutes
|
Assessed by 75 g oral glucose tolerance test
|
0-120 minutes
|
|
Insulin sensitivity
Time Frame: 0-120 minutes
|
Assessed during 75 g oral glucose tolerance test
|
0-120 minutes
|
|
Basal energy expenditure
Time Frame: 150 minutes after oral glucose challenge
|
Assessed by indirect calorimetry
|
150 minutes after oral glucose challenge
|
|
Change in hormone levels
Time Frame: 0-150 minutes
|
Change in adrenocorticotropic hormone (ACTH), growth hormone (GH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), fibroblast growth factor 21(FGF-21) after oral glucose challenge and start of glucagon/saline infusion.
|
0-150 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 529_2016BO1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.